1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,376 | 0,408 | 19:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| Mo | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - COMPLETION OF CAPITAL INCREASE OF A SUBSIDIARY | - | HKEx | ||
| Mo | IMMUNEONCO-B (01541): 2026 INTERIM REPORT | 2 | HKEx | ||
| 16.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.08. | IMMUNEONCO-B (01541): (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 27.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT ... | 1 | HKEx | ||
| 26.08. | IMMUNEONCO-B (01541): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003 | - | HKEx | ||
| 21.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE IB/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ... | 1 | HKEx | ||
| 14.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 31.07. | IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II/III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF IGG4-RELATED DISEASE | 2 | HKEx | ||
| 06.07. | IMMUNEONCO-B (01541): (REVISED) NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 03.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.07. | IMMUNEONCO-B (01541): ANNOUNCEMENT PURSUANT TO RULES 14A.36, 14A.39 AND 14A.46 OF THE LISTING RULES | - | HKEx | ||
| 24.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,190 | -1,37 % | EQS-News: CPT GmbH: Warren Wise entschlüsselt Qiagens DNA | EQS-News: CPT GmbH
/ Schlagwort(e): Research Update/Jahresbericht
Warren Wise entschlüsselt Qiagens DNA
25.09.2026 / 18:15 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,410 | +2,96 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| MODERNA | 172,66 | +1,64 % | Moderna vor Krebs-Durchbruch: Aktie auf 52-Wochen-Hoch | Moderna arbeitet weiter daran, sein Geschäft über die bekannten Covid-19-Impfstoffe hinaus auszubauen. Einen Einblick in die strategischen Prioritäten des US-Biotechnologiekonzerns gaben Moderna-Chef... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,070 | -1,45 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| DYNE THERAPEUTICS | 16,150 | +0,25 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 29,860 | -4,42 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 290,43 | -0,32 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| EVOTEC | 3,028 | -2,32 % | EQS-News: Evotec SE: Evotec kündigt Wechsel in der Position des Chief Scientific Officer an | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec kündigt Wechsel in der Position des Chief Scientific Officer an
29.09.2026 / 07:30 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 115,56 | 0,00 % | B.Riley reiterates Kymera Therapeutics stock rating on new trial data | ||
| BIONTECH | 86,80 | -0,23 % | PRESSESPIEGEL/Unternehmen: BIONTECH/ARIFE, BIONTECH, VOLKSWAGEN, SGB-SMIT, HSBC | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
BIONTECH/ARIFE - Die Biontech-Mitgründer Ugur Sahin und Özlem Türeci... ► Artikel lesen | |
| ABSCI | 10,905 | +1,30 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| IMMUNOVANT | 34,190 | +1,21 % | Immunovant (IMVT): One Trial Failure Doesn't Break the Bull Case | ||
| HARMONY BIOSCIENCES | 39,650 | +1,07 % | Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days | ||
| RELAY THERAPEUTICS | 18,810 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 75,44 | +1,16 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,002 (+0,56 %) liegt der Kurs bei 0,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.